Filing Flows › Comparisons › NBIX vs EXEL
Neurocrine Biosciences vs Exelixis: NBIX and EXEL compared
Neurocrine Biosciences is the larger company: $1.1B of revenue in its latest quarter (Q3 2026) against $659M for Exelixis (Q3 2026). Neurocrine Biosciences is growing faster (+41% against +10% a year earlier). Exelixis is more profitable, with an operating margin of 40.8% against 29.5%.
Where the money goes: NBIX and EXEL
Neurocrine Biosciences (NBIX) · Q3 2026
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Exelixis (EXEL) · Q3 2026
Exelixis, Q3 2026: revenue $659M (+10% year over year), operating margin 40.8%, net earnings $218M, operating cash flow $280M. The chart follows the revenue to costs, profit and cash.
| Neurocrine Biosciences (NBIX) | Exelixis (EXEL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.1B | $659M |
| Revenue growth, Y/Y | +41% | +10% |
| Operating margin | 29.5% | 40.8% |
| Net earnings | $206M | $218M |
| Net margin | 18.4% | 33.1% |
| Operating cash flow | $395M | $280M |
| Free cash flow | $384M | $277M |
| Market value | $17.3B | $17.8B |
| P/E | 24.4× | 20.8× |
| Analysts’ mean target | $208.11 | $61.57 |
Where the revenue comes from
Exelixis
- Net product revenues: $605M (92%)
- Collaboration: $53.8M (8%)
- COMETRIQ: $1.8M (0%)
Questions
Which is bigger, Neurocrine Biosciences or Exelixis?
Neurocrine Biosciences is the larger company: $1.1B of revenue in its latest quarter (Q3 2026) against $659M for Exelixis (Q3 2026).
Is Neurocrine Biosciences or Exelixis growing faster?
Neurocrine Biosciences is growing faster (+41% against +10% a year earlier).
Which is more profitable, Neurocrine Biosciences or Exelixis?
Exelixis is more profitable, with an operating margin of 40.8% against 29.5%.
More: Neurocrine Biosciences earnings · how Neurocrine Biosciences makes money · Exelixis earnings · how Exelixis makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.